The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy
CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2011-03, Vol.52 (5), p.671-673 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 673 |
|---|---|
| container_issue | 5 |
| container_start_page | 671 |
| container_title | Clinical infectious diseases |
| container_volume | 52 |
| creator | Waters, Laura J. Scourfield, Andrew T. Marcano, Marie Gazzard, Brian G. Bower, Mark Nelson, Mark Stebbing, Justin |
| description | CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism evolution during fully suppressive antiretroviral therapy (ART). Two of 37 patients showed evidence of switching. Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA. |
| doi_str_mv | 10.1093/cid/ciq198 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_888114645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>29777367</jstor_id><oup_id>10.1093/cid/ciq198</oup_id><sourcerecordid>29777367</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-4db245a7bdc07ea27167054e153b86f1ae1daff81c45429c8a6e0f1fe33f35933</originalsourceid><addsrcrecordid>eNp90c1rFDEYBvBBLLZWL96VUJCCMJpMPudYltouFFro6nXIZt5oltkkTTIL_e-N7OqCBw8hOfx43iRP07wj-DPBPf1i3FjXE-nVi-aMcCpbwXvysp4xVy1TVJ02r3PeYEyIwvxVc9qRru-E7M6aafUT0PUuTHNxwaNg0SIkMBBLSGiVQnR5i5xHt8vvrfMWTIERPejiwJeMlr5ASnMszv9Aj3OMCXJ2O0BXvrgEJYWdS3pCdUjS8flNc2L1lOHtYT9vvn29Xi1u27v7m-Xi6q41TNDSsnHdMa7lejRYgu4kERJzBvVpayUs0UBGba0ihnHW9UZpAdgSC5RayntKz5vLfW5M4WmGXIatywamSXsIcx6UUoQwwXiVF__ITZiTr5cbFGeYMkFERZ_2yKSQcwI7xOS2Oj0PBA-_GxhqA8O-gYo_HBLn9RbGv_TPl1fw8QB0NnqySXvj8tHRXkqK6dGFOf5_4Pu92-Ta2TGnxkgqJP0FIeumZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>854034616</pqid></control><display><type>article</type><title>The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Waters, Laura J. ; Scourfield, Andrew T. ; Marcano, Marie ; Gazzard, Brian G. ; Bower, Mark ; Nelson, Mark ; Stebbing, Justin</creator><creatorcontrib>Waters, Laura J. ; Scourfield, Andrew T. ; Marcano, Marie ; Gazzard, Brian G. ; Bower, Mark ; Nelson, Mark ; Stebbing, Justin</creatorcontrib><description>CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism evolution during fully suppressive antiretroviral therapy (ART). Two of 37 patients showed evidence of switching. Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciq198</identifier><identifier>PMID: 21292672</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; AIDS ; Anti-HIV Agents - administration & dosage ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antiretroviral Therapy, Highly Active ; Antiretrovirals ; Antiviral agents ; Arts ; Biological and medical sciences ; BRIEF REPORT ; Drug therapy ; Female ; HIV ; HIV - pathogenicity ; HIV 1 ; HIV Fusion Inhibitors - administration & dosage ; HIV Infections - drug therapy ; HIV Infections - virology ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Male ; Medical sciences ; Medical treatment ; Pharmacology. Drug treatments ; Pregnancy ; Proteins ; Ribonucleic acid ; RNA ; Toxicity ; Tropisms ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral load ; Viral Tropism ; Virology ; Viruses ; Withholding Treatment</subject><ispartof>Clinical infectious diseases, 2011-03, Vol.52 (5), p.671-673</ispartof><rights>Copyright © 2011 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2011. 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Mar 1, 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-4db245a7bdc07ea27167054e153b86f1ae1daff81c45429c8a6e0f1fe33f35933</citedby><cites>FETCH-LOGICAL-c463t-4db245a7bdc07ea27167054e153b86f1ae1daff81c45429c8a6e0f1fe33f35933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/29777367$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/29777367$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,1578,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23977303$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21292672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Waters, Laura J.</creatorcontrib><creatorcontrib>Scourfield, Andrew T.</creatorcontrib><creatorcontrib>Marcano, Marie</creatorcontrib><creatorcontrib>Gazzard, Brian G.</creatorcontrib><creatorcontrib>Bower, Mark</creatorcontrib><creatorcontrib>Nelson, Mark</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><title>The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism evolution during fully suppressive antiretroviral therapy (ART). Two of 37 patients showed evidence of switching. Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA.</description><subject>Adult</subject><subject>AIDS</subject><subject>Anti-HIV Agents - administration & dosage</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiretrovirals</subject><subject>Antiviral agents</subject><subject>Arts</subject><subject>Biological and medical sciences</subject><subject>BRIEF REPORT</subject><subject>Drug therapy</subject><subject>Female</subject><subject>HIV</subject><subject>HIV - pathogenicity</subject><subject>HIV 1</subject><subject>HIV Fusion Inhibitors - administration & dosage</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - virology</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Proteins</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Toxicity</subject><subject>Tropisms</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral load</subject><subject>Viral Tropism</subject><subject>Virology</subject><subject>Viruses</subject><subject>Withholding Treatment</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90c1rFDEYBvBBLLZWL96VUJCCMJpMPudYltouFFro6nXIZt5oltkkTTIL_e-N7OqCBw8hOfx43iRP07wj-DPBPf1i3FjXE-nVi-aMcCpbwXvysp4xVy1TVJ02r3PeYEyIwvxVc9qRru-E7M6aafUT0PUuTHNxwaNg0SIkMBBLSGiVQnR5i5xHt8vvrfMWTIERPejiwJeMlr5ASnMszv9Aj3OMCXJ2O0BXvrgEJYWdS3pCdUjS8flNc2L1lOHtYT9vvn29Xi1u27v7m-Xi6q41TNDSsnHdMa7lejRYgu4kERJzBvVpayUs0UBGba0ihnHW9UZpAdgSC5RayntKz5vLfW5M4WmGXIatywamSXsIcx6UUoQwwXiVF__ITZiTr5cbFGeYMkFERZ_2yKSQcwI7xOS2Oj0PBA-_GxhqA8O-gYo_HBLn9RbGv_TPl1fw8QB0NnqySXvj8tHRXkqK6dGFOf5_4Pu92-Ta2TGnxkgqJP0FIeumZA</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Waters, Laura J.</creator><creator>Scourfield, Andrew T.</creator><creator>Marcano, Marie</creator><creator>Gazzard, Brian G.</creator><creator>Bower, Mark</creator><creator>Nelson, Mark</creator><creator>Stebbing, Justin</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7U2</scope></search><sort><creationdate>20110301</creationdate><title>The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy</title><author>Waters, Laura J. ; Scourfield, Andrew T. ; Marcano, Marie ; Gazzard, Brian G. ; Bower, Mark ; Nelson, Mark ; Stebbing, Justin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-4db245a7bdc07ea27167054e153b86f1ae1daff81c45429c8a6e0f1fe33f35933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>Anti-HIV Agents - administration & dosage</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiretrovirals</topic><topic>Antiviral agents</topic><topic>Arts</topic><topic>Biological and medical sciences</topic><topic>BRIEF REPORT</topic><topic>Drug therapy</topic><topic>Female</topic><topic>HIV</topic><topic>HIV - pathogenicity</topic><topic>HIV 1</topic><topic>HIV Fusion Inhibitors - administration & dosage</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - virology</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Proteins</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Toxicity</topic><topic>Tropisms</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral load</topic><topic>Viral Tropism</topic><topic>Virology</topic><topic>Viruses</topic><topic>Withholding Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waters, Laura J.</creatorcontrib><creatorcontrib>Scourfield, Andrew T.</creatorcontrib><creatorcontrib>Marcano, Marie</creatorcontrib><creatorcontrib>Gazzard, Brian G.</creatorcontrib><creatorcontrib>Bower, Mark</creatorcontrib><creatorcontrib>Nelson, Mark</creatorcontrib><creatorcontrib>Stebbing, Justin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Safety Science and Risk</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waters, Laura J.</au><au>Scourfield, Andrew T.</au><au>Marcano, Marie</au><au>Gazzard, Brian G.</au><au>Bower, Mark</au><au>Nelson, Mark</au><au>Stebbing, Justin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>52</volume><issue>5</issue><spage>671</spage><epage>673</epage><pages>671-673</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism evolution during fully suppressive antiretroviral therapy (ART). Two of 37 patients showed evidence of switching. Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>21292672</pmid><doi>10.1093/cid/ciq198</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2011-03, Vol.52 (5), p.671-673 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_888114645 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult AIDS Anti-HIV Agents - administration & dosage Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiretroviral Therapy, Highly Active Antiretrovirals Antiviral agents Arts Biological and medical sciences BRIEF REPORT Drug therapy Female HIV HIV - pathogenicity HIV 1 HIV Fusion Inhibitors - administration & dosage HIV Infections - drug therapy HIV Infections - virology Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Male Medical sciences Medical treatment Pharmacology. Drug treatments Pregnancy Proteins Ribonucleic acid RNA Toxicity Tropisms Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral load Viral Tropism Virology Viruses Withholding Treatment |
| title | The Evolution of Coreceptor Tropism in HIV-infected Patients Interrupting Suppressive Antiretroviral Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T11%3A32%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Evolution%20of%20Coreceptor%20Tropism%20in%20HIV-infected%20Patients%20Interrupting%20Suppressive%20Antiretroviral%20Therapy&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Waters,%20Laura%20J.&rft.date=2011-03-01&rft.volume=52&rft.issue=5&rft.spage=671&rft.epage=673&rft.pages=671-673&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/cid/ciq198&rft_dat=%3Cjstor_proqu%3E29777367%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=854034616&rft_id=info:pmid/21292672&rft_jstor_id=29777367&rft_oup_id=10.1093/cid/ciq198&rfr_iscdi=true |